FY2026 EPS Estimate for Lexeo Therapeutics Lifted by Analyst

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Equities research analysts at Leerink Partnrs lifted their FY2026 EPS estimates for shares of Lexeo Therapeutics in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($2.54) for the year, up from their prior forecast of ($2.55). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ FY2027 earnings at ($2.50) EPS.

Other research analysts have also recently issued reports about the stock. HC Wainwright raised their price objective on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price objective on shares of Lexeo Therapeutics in a research note on Tuesday. Chardan Capital raised their price objective on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Leerink Partners dropped their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Wednesday, November 13th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and an average target price of $23.80.

Lexeo Therapeutics Trading Down 0.5 %

Shares of LXEO opened at $5.58 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. The firm has a 50 day simple moving average of $6.66 and a 200-day simple moving average of $9.28. Lexeo Therapeutics has a 1-year low of $4.67 and a 1-year high of $19.50. The stock has a market cap of $184.53 million, a price-to-earnings ratio of -1.77 and a beta of 3.08.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Lexeo Therapeutics during the fourth quarter worth approximately $46,000. SG Americas Securities LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $72,000. JPMorgan Chase & Co. boosted its holdings in shares of Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company’s stock valued at $93,000 after purchasing an additional 5,915 shares during the last quarter. Exome Asset Management LLC acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at $797,000. Finally, Barclays PLC boosted its holdings in shares of Lexeo Therapeutics by 162.2% in the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares during the last quarter. Institutional investors and hedge funds own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.